What is DiscGenics?
DiscGenics is a clinical-stage biotechnology firm dedicated to the development of innovative regenerative therapies for spinal health. The company's core competency lies in the engineering of Discogenic Cells, an allogeneic, injectable cell therapy designed to treat mild to moderate lumbar disc degeneration. By focusing on the biological restoration of the intervertebral disc, DiscGenics aims to provide a long-term solution for chronic back pain, moving beyond the symptomatic relief offered by current standard-of-care interventions. Their market position is defined by a commitment to rigorous clinical validation and the pursuit of transformative medical outcomes in the orthobiologics space.
How much funding has DiscGenics raised?
DiscGenics has raised a total of $71.9M across 5 funding rounds:
Series A
$7M
Series B
$14M
Debt
$350K
Series C
$50M
Debt
$562K
Series A (2013): $7M, investors not publicly disclosed
Series B (2017): $14M led by Mitsubishi Corporation
Debt (2020): $350K supported by PPP
Series C (2020): $50M featuring Ci:z Holdings Co. Ltd., Medical Incubator Japan K.K, Eagle Private Capital LLC, Mitsubishi UFJ Capital Co. Ltd, and CareNet of Japan
Debt (2021): $562K backed by PPP
Key Investors in DiscGenics
Mitsubishi Corporation
A global integrated business enterprise that develops and operates across diverse industries, including industrial finance, energy, and healthcare infrastructure.
Medical Incubator Japan K.K
A specialized venture capital firm focused on supporting the growth of innovative medical technology and healthcare startups in Japan.
Mitsubishi UFJ Capital Co. Ltd
The venture capital arm of the Mitsubishi UFJ Financial Group, providing strategic investment and support to high-growth technology and life science companies.
What's next for DiscGenics?
With the recent capital injection, DiscGenics is poised to advance its clinical development programs and refine its manufacturing processes for large-scale therapeutic delivery. The strategic focus remains on navigating the regulatory landscape to bring IDCT to market, potentially establishing a new standard for spinal regenerative medicine. Future growth will likely hinge on the successful completion of ongoing clinical trials and the expansion of their intellectual property portfolio. As the company transitions from a research-heavy entity to a commercial-ready organization, the integration of strategic partnerships will be critical in scaling their reach within the global healthcare market.
See full DiscGenics company page
